Amifampridine

Brand name: Firdapse

DILI Likelihood

Score E — Unlikely Hepatotoxin

Despite extensive use, there is no convincing evidence that this drug causes liver injury.

Single case reports may have been published, but they were largely unconvincing. The agent is not believed or is unlikely to cause liver injury.

Classification

Primary class CNS

Secondary class Myasthenia

FDA approval 2018